Daby Benjamine Carreras's questions to Immunoprecise Antibodies Ltd (IPA) leadership • Q3 2025
Question
Daby Benjamine Carreras expressed enthusiasm for the company's progress and requested more details about the internal GLP-1 therapeutic program developed using the company's AI platform.
Answer
CEO Jennifer Bath detailed the AI-driven GLP-1 program, explaining that the LENSai platform was used to design a differentiated molecule with improved stability and a unique profile to avoid existing patents. She highlighted that the program is advancing through partnerships for manufacturing and preclinical work, with a key focus on a novel transdermal patch delivery system. This approach aims to reduce injection frequency. Bath emphasized that the program is structured to showcase LENSai's capabilities through collaborations that cover costs, minimizing financial risk for ImmunoPrecise.